CLINICAL_TRIALS ClinicalTrials.gov record update

Trial of Interleukin-2 in Combination With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02748564
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:38.827411+00:00
Published At: 2023-02-09T00:00:00+00:00
Record Updated At: 2023-08-03
Results Posted At: 2023-02-09
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Metastatic Melanoma", "Stage III Mucosal Melanoma of the Head and Neck", "Stage IIIA Skin Melanoma", "Stage IIIB Skin Melanoma", "Stage IIIC Skin Melanoma", "Stage IV Skin Melanoma", "Stage IVA Mucosal Melanoma of the Head and Neck", "Stage IVB Mucosal Melanoma of the Head and Neck", "Stage IVC Mucosal Melanoma of the Head and Neck"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-08-03"
protocolSection.identificationModule.nctId: "NCT02748564"
protocolSection.identificationModule.officialTitle: "Trial of Interleukin-2 in Combination With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-02-09"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.